Zvi Schiffman, MD
Urology · Houston, TXNPI 1528036779
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (53.6%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 60 manufacturers reported payments, led by Pfizer at 25.7% of the total. Among urology clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 589 payments — averaging $54.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$8K
- Avyxa Pharma, LLC$3K
- Bayer$2K
- Palette Life Sciences, Inc.$2K
- Johnson & Johnson$2K
- Boston Scientific$1K
- plus $13K from 54 others
Across 1,106 payments — averaging $16,078 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$10M
- Medivation LLC.$3.4M
- Palette Life Sciences, Inc.$1.8M
- Merck$909K
- Janssen Research & Development, LLC$733K
- Veru Inc.$421K
- plus $464K from 7 others
What the payments were for
- Consulting fees$2,8349%
- Speaking & faculty fees$7,12122%
- Travel & lodging$4,73015%
- Food & beverage$17,05154%
- Education$690%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XTANDI$3,293
- Xofigo$1,880
- AQUABEAM SYSTEM$740
- Erleada$363
- PROVENGE$324
- SpaceOAR VUE System - 10mL$293
- GENERAL BPH$223
- AMS 700 CXR RTE KIT$148
- AquaBeam Robotic System$148
- iTIND System$146
- CAMCEVI$137
- AKEEGA$137
- Olympus Laser Devices$135
- Olympus Digital Flexible Ureteroscopes$135
- RYBREVANT$132
- CARVYKTI$132
- Nubeqa$126
- UroLift$125
- XT CDX$125
- Barrigel$124
How this compares
$31,804 in reported general payments places this provider in the 90th percentile of 878 urology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 76 | $966,986 |
| NubeqaDarolutamide | 19 | $252,482 |
| MyrbetriqMirabegron | 67 | $77,536 |
| Abiraterone Acetate | 18 | $41,403 |
| GemtesaVibegron | 28 | $22,748 |
| Tamsulosin Hcl | 797 | $10,412 |
| Finasteride | 696 | $9,942 |
| Oxybutynin Chloride ErOxybutynin Chloride | 288 | $7,363 |
| Testosterone | 68 | $3,243 |
| Desmopressin Acetate | 43 | $2,233 |
| Potassium Citrate ErPotassium Citrate | 22 | $1,847 |
| Solifenacin Succinate | 15 | $1,544 |
| Dutasteride | 49 | $1,257 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 73 | $1,100 |
| Ciprofloxacin Hcl | 202 | $895 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $855 | $1,044,523143 claims |
| BayerNubeqa | $2,469 | $252,48219 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $954 | $41,40318 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $408 | $22,74828 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 878 urology providers in Texas.
Other urology in Houston
- Arun RaiHouston$920K
- Donald GriffithHouston$732K
- Jonathan Clavell HernandezHouston$500K
- Ashish KamatHouston$481K
- Mohit KheraHouston$428K
- Ricardo GonzalezHouston$314K
- Richard LinkHouston$261K
- Steven CanfieldHouston$256K
- Run WangHouston$195K
- Kathleen KobashiHouston$159K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.